HeraMED (ASX:HMD) completes HeraBEAT trial with “excellent” results – The Market Herald
- Pregnancy technology company HeraMED (HMD) completes HeraBEAT clinical trial with Israel’s Sheba Medical Center with “excellent” results
- A total of 10 patients were recruited into the study and underwent a telemedicine observation visit using HeraBEAT
- The trial measured patients’ first in-person visit versus telemedicine encounter with a 60% reduction in online meeting
- HeraBEAT allows expectant mothers to monitor their fetal heart rate anytime, anywhere and share data with healthcare professionals
- HeraMED ends the day in the gray with shares trading at 12 cents
Pregnancy technology company HeraMED (HMD) has completed the HeraBEAT clinical trial with Israel’s Sheba Medical Center with “excellent” results.
The study was led by Sheba Women’s Health Innovation Center Director and OBGYN Beyond Dr. Avi Tsur to determine the feasibility of expanding pregnancy capabilities remotely.
A total of 10 patients were recruited into the study and underwent a telemedicine observation visit using HeraBEAT.
The trial measured patients’ first in-person visit against the telemedicine encounter.
Notably, there was a 60% reduction in time spent on the telemedicine visit, potentially saving patients and staff over 2.5 hours.
The study concluded that remote assessment is feasible, saves time and leads to higher levels of patient satisfaction. It also confirmed the clinical, economic, social and logistical benefits.
HeraBEAT is a smartphone-based fetal heart rate monitor designed for home use, allowing expectant mothers to monitor their fetal heart rate anytime, anywhere.
The data can then be stored and shared with medical professionals, allowing parents to rest while their fetus receives medical care.
“We are excited about the results of this Sheba study, which indicate, once again, that our HeraBEAT fetal and maternal heart rate monitor is helping to break down the technology barriers that previously prevented the provision of effective remote monitoring via telemedicine. for pregnant women,” CEO and co-founder David Groberman commented.
“An added benefit in the current environment is that the remote monitoring functionality provided by HeraBEAT also helps limit the spread of the COVID-19 pandemic among pregnant women.
HeraMED ended the day in the gray with shares trading at 12 cents.